In addition, circMYBL2 induces resistance to quizartinib, a potent and highly selective FLT3 inhibitor, in FLT3-ITD+ AML cells by activating FLT3 kinase-dependent signalling pathways [46]. This evidence concerns the gene FLT3 and acute myeloid leukemia.